March 8, 2010 – Six-month follow-up data on the Stentys drug-eluting and bare metal stents showed a 4 percent restenosis rate in complex lesions.
Results from the OPEN-I clinical study were recently presented by Stefan Verheye, M.D., Ph.D., at the Joint Interventional Meeting (JIM) 2010 in Rome. The results demonstrated superior results in 60 patients (27 Stentys drug-eluting stents and 33 Stentys bare-metal stents) who were followed–up angiographically after six months.
“These clinical results suggest very promising benefits for patients,” said Dr. Verheye, department of cardiology, Middelheim Hospital, Antwerp, Belgium. “We had already demonstrated that the self-expanding and disconnectable Stentys platform ensured optimal wall apposition and easy access to side branches. We can now confirm that the addition of a drug coating eliminates the need for reintervention.”
The company said these data fortify the superiority of self-expanding and drug-eluting stents over balloon-expandable DES for the treatment of complex cases.
In December 2009 Stentys started enrolling patients in the randomized APPOSITION II clinical trial to compare the Stentys self-expanding stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth.
For more information: www.stentys.com
April 24, 2024 
